CAR-T cells are serial killers.

abstract：:The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunity requires FPR1 and...

journal_title：Oncoimmunology

authors： Baracco EE,Pietrocola F,Buqué A,Bloy N,Senovilla L,Zitvogel L,Vacchelli E,Kroemer G

更新日期：2016-02-18 00:00:00

abstract：:RIG-I-like helicases (RLH) are cytosolic sensors for viral RNA inducing type I interferon production. We found that pancreatic cancer cells express functional RLH and are susceptible to RLH-induced apoptosis via intrinsic and extrinsic pathways. Tumor cells displayed features of immunogenic cell death resulting in den...

journal_title：Oncoimmunology

authors： Schnurr M,Duewell P

更新日期：2014-12-13 00:00:00

abstract：:Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical responses in hematological malignancies. Prostate cancer may be amenable to T cell-based immunotherapy since several tumor antigens, ...

journal_title：Oncoimmunology

authors： Priceman SJ,Gerdts EA,Tilakawardane D,Kennewick KT,Murad JP,Park AK,Jeang B,Yamaguchi Y,Yang X,Urak R,Weng L,Chang WC,Wright S,Pal S,Reiter RE,Wu AM,Brown CE,Forman SJ

更新日期：2017-10-16 00:00:00

abstract：:Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a novel or reinstating a pre-existing antitumor immune response. Most often, immunostimulatory mAbs activate T lymphocytes or natural killer (NK) cells by inhibiting immunosuppressive receptors, such as cytotoxic T lymphocyte-asso...

journal_title：Oncoimmunology

authors： Aranda F,Vacchelli E,Eggermont A,Galon J,Fridman WH,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2014-01-01 00:00:00

abstract：:A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can wo...

journal_title：Oncoimmunology

authors： O'Konek JJ,Ambrosino E,Bloom AC,Pasquet L,Massilamany C,Xia Z,Terabe M,Berzofsky JA

更新日期：2018-04-09 00:00:00

abstract：:Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant subgroups to improve our understanding of pathogenetic mechanisms and patient stratification. Concurrently, the role of immune cells i...

journal_title：Oncoimmunology

authors： Kaffes I,Szulzewsky F,Chen Z,Herting CJ,Gabanic B,Velázquez Vega JE,Shelton J,Switchenko JM,Ross JL,McSwain LF,Huse JT,Westermark B,Nelander S,Forsberg-Nilsson K,Uhrbom L,Maturi NP,Cimino PJ,Holland EC,Kettenmann H,

更新日期：2019-08-22 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broa...

journal_title：Oncoimmunology

authors： Somaiah N,Chawla SP,Block MS,Morris JC,Do K,Kim JW,Druta M,Sankhala KK,Hwu P,Jones RL,Gnjatic S,Kim-Schulze S,Tuballes K,Yishak M,Lu H,Yakovich A,Ter Meulen J,Chen M,Kenney RT,Bohac C,Pollack SM

更新日期：2020-11-19 00:00:00

abstract：:Immune tolerance induced by regulatory mechanisms is an integral and fundamental part of immunity. In therapeutic settings, however, tolerance may significantly limit efficacy. Here, we summarize possible strategies to enhance therapeutic antibody dependent cellular cytotoxicity by overcoming NK cell tolerance. ...

journal_title：Oncoimmunology

authors： Terszowski G,Klein C,Schmied L,Stern M

更新日期：2015-04-02 00:00:00

abstract：:Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (G...

journal_title：Oncoimmunology

authors： Pandey JP,Kaur N,Costa S,Amorim J,Nabico R,Linhares P,Vaz R,Viana-Pereira M,Reis RM

更新日期：2014-05-23 00:00:00

abstract：:A number of studies point to an aberrant differentiation and accumulation of CD14+ PD-L1+ M2-macrophage-like cells in the microenvironment of cervical cancer, which promote immunosuppressive conditions and are associated with tumor invasion, angiogenesis and metastasis. Therapeutic targeting of these macrophages may t...

journal_title：Oncoimmunology

authors： Heeren AM,Kenter GG,Jordanova ES,de Gruijl TD

更新日期：2015-05-07 00:00:00

abstract：:Estrogen receptors have recently been demonstrated at the cell surface. Unlike nuclear receptors, they are able to trigger rapid responses inside the cells. In this study, we evaluated the presence and the possible role of autoantibodies specific to estrogen receptor (anti-ER Abs) in the peripheral blood of breast can...

journal_title：Oncoimmunology

authors： Maselli A,Capoccia S,Pugliese P,Raggi C,Cirulli F,Fabi A,Malorni W,Pierdominici M,Ortona E

更新日期：2015-08-12 00:00:00

abstract：:High-dose chemotherapy may kill not only tumor cells but also immunocytes, and frequently induces severe lymphocytopenia. On the other hand, patients who recover from the nadir maintain immunity against infection, suggesting the existence of an unknown memory T-cell population with stress resistance, long-living capac...

journal_title：Oncoimmunology

authors： Murata K,Tsukahara T,Emori M,Shibayama Y,Mizushima E,Matsumiya H,Yamashita K,Kaya M,Hirohashi Y,Kanaseki T,Kubo T,Himi T,Ichimiya S,Yamashita T,Sato N,Torigoe T

更新日期：2016-06-08 00:00:00

abstract：:Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

journal_title：Oncoimmunology

authors： Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

更新日期：2017-06-20 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:Immune suppression is recognized as a hallmark of cancer and this notion is largely based on studies on cellular immunity. Our recent studies have demonstrated a potential new mechanism of cancer suppression of immunity by impairment of antibody effector function mediated by proteolytic enzymes in the tumor microenvir...

journal_title：Oncoimmunology

authors： Zhang N,Jordan RE,An Z

更新日期：2015-12-29 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

journal_title：Oncoimmunology

authors： Su WP,Wang WJ,Sze CI,Chang NS

更新日期：2016-07-28 00:00:00

abstract：:Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

journal_title：Oncoimmunology

authors： Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

更新日期：2018-09-26 00:00:00

abstract：:The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

journal_title：Oncoimmunology

authors： Lanzi A,Sinicrope FA,Benson AB,Galon J

更新日期：2020-07-20 00:00:00

abstract：:Cell signals integral to the tumor microenvironment influence cancer progression. Tumor-associated myeloid cells secrete pro-tumorigenic agents including, but not limited to, the potent cytokine transforming growth factor β (TGFβ). We have discovered a network of extrinsic signals including delta-like 4 (Dll4), Notch ...

journal_title：Oncoimmunology

authors： Ohnuki H,Tosato G

更新日期：2014-05-23 00:00:00

abstract：:Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a novel treatment approach involving repeated subcutaneous delivery of a ...

journal_title：Oncoimmunology

authors： Bazett M,Costa AM,Bosiljcic M,Anderson RM,Alexander MP,Wong SWY,Dhanji S,Chen JM,Pankovich J,Lam S,Sutcliffe S,Gunn H,Kalyan S,Mullins DW

更新日期：2017-11-27 00:00:00

abstract：:Surgical resection is the mainstay of treatment for solid tumors, but the postoperative period is uniquely inclined to the formation of metastases, largely due to the suppression of natural killer (NK) cells. We found that preoperative influenza vaccination prevents postoperative NK-cell dysfunction, attenuating tumor...

journal_title：Oncoimmunology

authors： Tai LH,Zhang J,Auer RC

更新日期：2013-11-01 00:00:00

abstract：:Anticancer immunotherapies are highly desired. Conversely, unwanted inflammatory or immune responses contribute to oncogenesis, tumor progression, and cancer-related death. For non-immunogenic therapies to inhibit tumor growth, they must promote, not prevent, the activation of anticancer immune responses. Here, the ce...

journal_title：Oncoimmunology

authors： Issazadeh-Navikas S

更新日期：2013-12-01 00:00:00

abstract：:CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

journal_title：Oncoimmunology

authors： Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

更新日期：2018-02-01 00:00:00

abstract：:Amino-bis-phosphonates (N-BPs) such as zoledronate (Zol) have been used in anticancer clinical trials due to their ability to upregulate pyrophosphate accumulation promoting antitumor Vγ9Vδ2 T cells. The butyrophilin 3A (BTN3A, CD277) family, mainly the BTN3A1 isoform, has emerged as an important structure contributin...

journal_title：Oncoimmunology

authors： Zocchi MR,Costa D,Venè R,Tosetti F,Ferrari N,Minghelli S,Benelli R,Scabini S,Romairone E,Catellani S,Profumo A,Poggi A

更新日期：2017-01-06 00:00:00

abstract：:Pancreatic cancer is characterized by expanded stroma with marked fibrosis. In Ijichi et al., we show that inhibiting CXCR2 disrupts tumor-stromal interactions and improves survival of a genetically-engineered mouse model recapitulating human pancreatic cancer. Targeting CXCLs/CXCR2 axis in the tumor microenvironment ...

journal_title：Oncoimmunology

authors： Ijichi H

更新日期：2012-07-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

journal_title：Oncoimmunology

authors： Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

更新日期：2018-10-31 00:00:00

abstract：:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

journal_title：Oncoimmunology

authors： Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

更新日期：2016-04-25 00:00:00